A NEW weight loss jab that only needs to be taken once monthly leads to “substantial weight loss”, according to early trials.

In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained ...

Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves ...

The once-monthly drug is still under study but could provide added convenience and another option for patients.

The new weight loss drug which is set to give Ozempic and Mounjaro a run for their money, MariTide, is taken on a monthly ...

Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

MariTide is designed to combine the effects of glucagon-like peptide-1 (GLP-1) receptor activation with glucose-dependent ...

Drugs such as Ozempic (a brand name for semaglutide) are showing promise for weight loss. Another medication in the same ...

A new experimental drug meant to be taken just once a month could lead to “substantial weight reduction” within a year and ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...